NLRP3 and metabolic dysfunction-associated steatohepatitis: Gan et al. (2022) showed that FTO, through demethylation of IL-17RA, enhanced its expression, thereby promoting liver inflammation. In the context of NASH development induced by arsenic exposure and hepatic insulin resistance, Qiu et al. (2023) found that METTL14 and IGF2BP2 contributed to the stabilization of NLRP3 mRNA, subsequently promoting NLRP3 inflammasome activation and resulting in the release of IL-1β and IL-18 (Figure 3).